Skip to main content

Table 1 Baseline patient demographics and disease characteristics (intent-to-treat population)

From: Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

  Simeprevir 75 mg + TMC647055/ritonavir 450/30 mg Simeprevir 75 mg + TMC647055/ritonavir 600/50 mg Simeprevir 75 mg + TMC647055/ ritonavir 450/30 mg + JNJ-56914845 30 mg Simeprevir 75 mg + TMC647055/ritonavir 450/30 mg + JNJ-56914845 60 mg
  Panel 1 Panel 2 Panel 3 Panel 4
  GT1a/with ribavirin (n = 10) GT1b/with ribavirin (n = 12) GT1b/without ribavirin (n = 9) GT1a/with ribavirin (n = 7) GT1b/without ribavirin (n = 8) GT1a/b/other (n = 22)a GT1a/b/other (n = 22)b
Caucasian, n (%) 10 (100) 12 (100) 8 (89) 7 (100) 6 (75) 20 (91) 21 (96)
Male, n (%) 8 (80) 4 (33) 7 (78) 7 (100) 3 (38) 16 (73) 17 (77)
Treatment-naïve, n (%) 10 (100) 8 (67) 8 (89) 7 (100) 4 (50) 20 (91) 19 (86)
Prior relapser, n (%) 0 (0) 4 (33) 1 (11) 0 (0) 4 (50) 2 (9) 3 (14)
Age, median, years (range) 46.5 (38–52) 47.5 (29–62) 37.0 (18–64) 44.0 (28–58) 48.5 (43–66) 50.5 (24–70) 48.0 (27–58)
HCV RNA, median, log10 IU/mL (range) 6.52 (4.4–7.2) 6.69 (5.8–7.5) 5.98 (5.3–7.1) 6.32 (6.0–7.4) 6.76 (6.1–7.0) 6.78 (5.5–7.4) 6.62 (5.2–7.1)
METAVIR score, n (%)
 F0–F2 5 (50) 6 (50) 6 (67) 4 (29) 3 (38) 7 (32) 5 (23)
 F3 1 (10) 1 (8) 1 (11) 1 (14) 0 2 (9) 4 (18)
 Missing 4 (40) 5 (42) 2 (22) 2 (29) 5 (63) 13 (59) 13 (59)
IL28B genotype, n (%)
 CC 5 (50) 4 (33) 2 (22) 0 (0) 2 (25) 9 (41) 6 (27)
 CT 4 (40) 6 (50) 6 (67) 6 (86) 5 (63) 8 (36) 11 (50)
 TT 1 (10) 2 (17) 1 (11) 1 (14) 1 (13) 5 (23) 5 (23)
  1. GT genotype, HCV hepatitis C virus
  2. aGT1a/other, n = 14; GT1b, n = 8. GT1a/other includes one patient with HCV GT1c and one patient with GT1l, as determined by NS5B sequencing
  3. bGT1a/other, n = 15; GT1b, n = 7